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This paper reviews efforts on using high energy (25-30 MeV) and high power 
(10-20 kW) electron linacs and lower energy (7 MeV) proton linacs for medical 
radioisotope production. Using high energy x-rays from the electron linacs, PET 
(Positron Emission Tomography) radioisotopes are produced through photonuclear 
reactions such as 19F(γ,n)18F, which also allow production of other PET 
radionuclides 11C, 13N, and 15O. Other mostly used medical radionuclides 99mTc can 
also be obtained by using the electron linacs, through photofission or photonuclear 
reactions.  Proton linacs for PET have also been recently developed and the product 
has been available in the market since 2005.  The linacs have been tested for 18F 
production. As a proton accelerator, the target systems and nuclear reactions are 
similar to the ones used in PET cyclotrons. 
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INTRODUCTION∗ 
 
In the medical world, linear accelerators 
(linacs) particularly electron linacs, are mostly used 
to generate high energy electron beam to be used 
directly or converted to high energy photon for 
gamma therapy, mostly for cancer treatment.  
Medical isotope production for diagnostics such as 
99mTc is carried out by neutron irradiation in nuclear 
reactors, or in the case of short-lived isotopes such 
as 18F for PET (Positron Emission Tomography) by 
using cyclotrons. 
However some studies on using high energy 
(25-30 MeV) and high power (10-20 kW) electron 
linacs for medical isotope production through 
photonuclear reactions such as 19F(γ,n)18F, which 
can use  19F  of natural (100%) abundance as target, 
had been carried out. This is in contrast with 
18O(p,n)18F of proton reactions which require 
expensive gas targets enriched with isotopes 18O in 
production using cyclotrons. Similar photonuclear 
reactions also allow production of other PET 
radionuclides 11C, 13N, and 15O. Other medical 
radionuclides such as 99mTc can also be obtained on 
electron accelerators, which cannot be obtained by 
using cyclotrons. Due to this reason the use of 
electron linacs is not only for gamma therapy, but 
also as a tool of production of radionuclides for 
diagnostics [1]. 
Ion linacs for PET has also been recently 
developed by Hitachi, Ltd. and AccSys Technology, 
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   E-mail address:  pramudita@batan.go.id 
Inc. (Hitachi's subsidiary company) and the product 
has been available in the market since 2005.  The 
AccSys PULSAR-7 is a radiofrequency linear 
proton (H+) accelerator for PET radionuclide 
production consisting of 30 keV duoplasmatron ion 
source, 3.5 MeV RFQ (radiofrequency quadrupole) 
first stage accelerator, 7 MeV DTL (drift tube linac) 
second stage accelerator, shielded PET radionuclide 
target system, and PC-based control system [2].  
The accelerator, with the beam transport line, is 
approximately 6.1 m long, weighs approximately              
3 tons and the target system shield weighs 
approximately 9 tons. All of these units are mounted 
in a medical coaches 16 m semi-trailer.  As a proton 
accelerator, the target system is similar to the one in 
PET cyclotron. However, as a linear proton 
accelerator it saves the weight and complexity of 
cyclotron magnet (minimum weight of about               
14 tons of magnet and its mechanical design for 
optimum focusing and relativistic correction) [3]. 
 
 
ELECTRON LINACS 
 
PET Radionuclides 
 
Photonuclear cross sections yielding PET 
radionuclides 15O, 13N, 11C from respectively natural 
abundant  isotopes all peaks at about 25 MeV of 
photon energy (Figs. 1a-c).  A neutron knocked off 
from a stable isotope yields a proton rich or positron 
emitter isotope which is applicable for PET. 
Experiments using photons from linacs at this 
energy had been carried out by Mac Gregor (1957) 
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[4], Lutz (1969) [5], and Dovbnya et al. (1999) [1]. 
The result is resumed in Table 1. The most popular 
PET radionuclide 18F was obtained at specific 
activities in the order of 106 Bq/g or 102 µCi per µA 
of linac electron beam current by using photonuclear 
reactions at 25 MeV [1]. Data on production of 15O 
at various electron linacs are given in Table 2. 
 
 
 
 
(a) 
 
 
 
(b) 
 
 
 
(c) 
 
Fig. 1.  Photonuclear cross sections for 16O, 14N, 12C yielding 
PET radionuclides, all peaks at about 25 MeV of photon              
energy [6].  
 
Table 1. Specific activities (in Bq/g per µA of linac electron 
beam current) of some PET radionuclides obtained by using 
photonuclear reactions at 25 MeV [1]. 
 
Radio-
nuclide 
Mac Gregor 
(1957) 
Lutz 
(1969) 
Dovbnya et 
al. (1999) 
11C 9.25×106 
 
5.30×106 1.90×106 
13N 3.76×106 1.04×106 1.67×106 
15O 3.20×106 8.40×106 2.50×106
18F 2.04×106 2.12×106 1.70×106
 
 
Table 2. Comparative data on production of 15O at various 
electron linacs [1]. 
 
 
 
Data on 
Center of 
Nuclear 
Medicine, 
Cincinnati, 
USA (1982)[7] 
 
Kurchatov, 
IAE, 
Moscow 
(1985)[8] 
 
NSC KIPT, 
Kharkov 
(1999)[1] 
 
Irradiation 
conditions 
 
E0 = 26 MeV 
Iav = 100 µA 
Tirr = 4 min  
V = 500 cm3 
 
E0 = 30 MeV 
Iav = 100 µA  
Tirr = 7 min  
V = 200 cm3 
E0 = 25 MeV  
Iav = 300 µA  
Tirr = 10 min  
V = 200 cm3 
Integral 
activity 
184 mCi  
(6.8×109 Bq) 
700 mCi 
(25.9×109 Bq) 
130 mCi 
(4.8×109 Bq) 
 
Target for photon irradiations is simpler in 
preparation as it is not subjected to direct beam 
heating as in the case of proton or deuteron 
irradiations. The beam heating is mostly borne by 
the heavy metal target (tungsten) converting the 
electron beam energy into photons at up to about 
50% efficiency. Because target nuclides are 
composed of naturally abundant isotopes, isotopic 
enrichment is therefore not required. The design of 
the target can also take into account the high 
penetrability of photons. 
The only drawbacks of photonuclear 
processes are the cross sections which are one to 
two orders smaller than those of nuclear reactions of 
proton or deuteron. Figure 1 shows cross sections in 
the order of millibarn, as compared to hundreds of 
millibarn cross sections of proton or deuteron 
irradiations at lower energy thresholds in Fig. 2              
and Fig. 3. 
 
 
 
Fig. 2. Deuteron cross sections on 14N yielding PET 
radionuclide 15O [9]. 
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Non-PET Medical Radionuclides 
 
Currently it is about 80% of the yearly 
worldwide 40 million nuclear medicine procedures 
use 99Mo.  The 99Mo isotope has been traditionally 
manufactured using nuclear reactors to irradiate 
highly enriched uranium targets. The Canada’s 
National Research Universal (NRU) reactor at 
Chalk River, which produces about half of the 
world’s supply, has been operating since 1957 and 
suffered from age-related shutdowns. The advances 
in accelerators enable high beam power to produce 
medical isotopes [10,11]. 
One favored approach uses photons from a 
high-power electron linear accelerator to produce 
99Mo from natural uranium through photonuclear 
reaction γ + 238U → 99Mo +  13xSn + 2D + …....... 
The radiochemistry to recover and refine the 99Mo 
generated through photofission from natural 
uranium target is similar to which is currently in 
using for reactors highly enriched uranium targets.  
Canada’s five-year plan (2010–1015) for TRIUMF 
includes the construction and operation of a high-
power (5 MW) electron linear accelerator. A single 
multimegawatt machine could supply the entire 
Canadian market or 5–7% of the total North 
American market [10,12]. 
Another approach at Yerevan Physics 
Institute (YerPhI) in Armenia is to use 100Mo target 
through photonuclear reaction γ + 100Mo → 99Mo + n, 
99Mo (T½ = 67 hours) → 99mTc (T½ = 6 hours), with 
threshold of reaction at 9.1 MeV. Unlike uranium 
target, this approach gives high purity isotopes and 
free from other radioisotopes which otherwise 
should be removed as wastes. The project was 
started at 2006 with collaborators from University 
of British Columbia/TRIUMF, Canada [13]. 
To produce 99mTc, the existing linear high 
current electron accelerator (I = 250 µA and                
E = 20 MeV) at YerPhI was used to irradiate a 20 g 
target of enriched 100Mo for 100 hours to produce 
approximately 20-40 Ci of 99mTc isotope, which 
correspond to about 5 Ci or 1.85×1011 Bq/day. This 
amount would satisfy the requirements of Armenia 
and neighboring regional countries. Once it is 
successfully proven, enough radioisotopes could be 
provided for direct use in Armenia as well as for 
potential clients (according to list of  IAEA). 
 
ION LINACS 
 
PET Radionuclides 
 
The feasibility of using compact ion linacs for 
medical applications had been studied for both 
particle radiation therapy [14] and isotope 
production [15]. Since 2005 Hitachi, Ltd. and 
AccSys Technology, Inc. (Hitachi's subsidiary 
company) manufactured a linear accelerator-based 
system for PET radiopharmaceuticals production.  
The system has the advantages of lower installation 
cost and complexity for areas where a large 
production center may not economically              
justified [2]. 
The AccSys PULSAR®-7 is a radiofrequency 
linear proton (H+) accelerator system for PET 
radionuclide production. It consist of H+ 
duoplasmatron ion source (30 keV), radiofrequency 
quadrupole (RFQ) as first stage accelerator (up to 
3.5 MeV), drift tube linac (DTL) as second stage 
accelerator (up to 7 MeV), shielded PET 
radionuclide target system, and a PC-based control 
system.  The proton energy of 7 MeV is sufficient to 
produce PET radionuclide 18F (Fig. 3). 
 
 
 
Fig. 3. Proton cross sections for 18O(p,n)18F  yielding PET 
radionuclides 18F.[16]. 
 
In August to September 2006 Wisconsin 
Medical Cyclotron (WMC) facility in West Allis, 
Wisconsin, tested the PULSAR®-7 in a mobile 
configuration, mounted in a Medical Coaches 16 m 
semi-trailer (Fig. 4). The semi-trailer was located on 
a parking area without additional parking  pad or 
support. On-board equipment included a 
radiopharmaceutical synthesis quality testing 
laboratory, and patient dose preparation equipment. 
For the evaluation tests, [18F] FDG qualification and 
unit dose preparation were carried out in the WMC 
facility. 
 
Fig. 4. AccySys PULSAR®-7 in a mobile configuration, 
mounted in a Medical Coaches 48 ft semi-trailer [2]. 
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The drift tube linac produces a pulsed beam 
of 125 µs length at  85 Hz repetition rate at a beam 
current of 9 mA with a 1% duty cycle.  The target 
system uses a support grid over a titanium target 
window to aid in cooling and support the 
pressurized target (about 315 psi). The transmission 
of beam through the grid is about 65%. Two thin 
target bodies, one made of silver and one made of 
niobium, were evaluated each with an 18O water 
capacity of 0.35 ml. A one hour bombardment yield 
634 mCi 18F and a two hour 1068 mCi. This 
production was lower than one observed at a similar 
fixed (not mobile) unit, which has routinely 
produced over a Ci/hour. This was most likely 
caused by marginal chiller in the mobile system 
which restricted power to lower sustained beam 
current and caused interrupted bombardment. The 
trailer cooling system was later rebuilt by the 
manufacturer. The beam alignment might be also 
slightly offset, resulting in a beam transmission 
through the grid of less than 65%. 
The trial has demonstrated the mobile proton 
linac unit to achieve a 94% 18F production batch 
reliability, to perform multiple daily bombardments 
of several hours, to produce 18F suitable for [18F] 
FDG manufacture for small scale distribution, and 
the product met quality standard. 
 
 
CONCLUSIONS 
 
The electron and proton linear accelerators 
have been proven to have feasibility for medical 
isotope production, which at present mostly 
produced commercially by using cyclotrons or 
nuclear reactors. For the electron accelerators, 
however, due to lower cross sections and higher 
energy thresholds, further efforts are still underway 
to prove that it is commercially feasible. As for the 
proton linear accelerators, fixed and mobile compact 
models have been developed and commercially 
available, providing more choices other than 
compact or baby cyclotrons, which could be 
considered for installation. 
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